Clinical Trial Update: First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 first-line trial of tamibarotene in combination for advanced non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tamibarotene (tamibarotene)

Snippet

Sponsor: CytRx | Conditions: Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion, Stage IV Non-small Cell Lung Cancer | Phase 2 | Status: TERMINATED